Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment- Study 2|
- Comparison of Active treatment vs. Watchful waiting/active surveillance at 3 and 6 months [ Time Frame: 3 and 6 month follow-up ] [ Designated as safety issue: No ]Men who review a DESI before making a treatment decision will be more likely to choose active surveillance/watchful waiting and will have better decision-specific knowledge.
- DESI viewing [ Time Frame: 3 month follow-up (phone survey) ] [ Designated as safety issue: No ]Decision aid viewing is a self-reported measures. Patients will be asked if they viewed the DVD that was given to them (intervention group)prior to them making a treatment choice decision.
- Healthcare utilization [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]Research staff will review EMR data to access decision-making outcomes and resource utilization.
|Study Start Date:||December 2010|
|Study Completion Date:||January 2013|
|Primary Completion Date:||January 2013 (Final data collection date for primary outcome measure)|
|No Intervention: Usual care|
|Experimental: Prostate cancer treatment DESI||
Behavioral: Prostate cancer treatment DESI
DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
Other Name: Decision Support Intervention
Potentially eligible men (age 45 and older who have localized prostate cancer with a Gleason score of 6 or less) will be identified and recruited to participate in the study before their next office visit. Patients who are interested and provide informed consent will be asked to complete a brief survey about background, medical history, knowledge of prostate cancer and health-related quality of life. Once the survey is completed the patient will be randomly assigned to one of 2 groups. Those assigned to the "Usual Care" group will not receive any additional information materials as part of their participation in the study. Those assigned to the "Patient Decision Support" group will receive a DVD program that contains information about treatment choices for prostate cancer.
Participants will be asked to answer a brief telephone survey at 3 and 6 months from the day of their last office visit. Survey questions will ask about knowledge about prostate cancer, health-related quality of life, whether or not the DVD was viewed and what treatment decision was made.
Research staff will also review medical records 6 months after enrollment to determine which treatment was received for prostate cancer, how many visits with health care providers were completed since enrollment and which medical services and procedures were received.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01244568
|United States, California|
|Palo Alto Medical Foundation Research Institute|
|Palo Alto, California, United States, 94301|
|United States, North Carolina|
|University of North Carolina, Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Carmen L Lewis, MD, MPH||University of North Carolina, Chapel Hill|
|Principal Investigator:||Ming Tai-Seale, Ph.D, MPH||Palo Alto Medical Foundation|